Overview

An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19

Status:
Active, not recruiting

Trial end date:
2020-07-01

Target enrollment:

Participant gender:

Summary

The study is Phase II/III and consists of pilot and pivotal stages. The objective of the pilot stage is to conduct a preliminary assessment of the efficacy and safety of Favipiravir, and to select the optimal dosing regimen to study during the pivotal stage. The objective of the pivotal stage is to assess the efficacy and safety of Favipiravir compared with the Standard of care (SOC) in hospitalized patients with moderate to severe COVID-19 pneumonia.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Chromis LLC

Collaborator:

Chemical Diversity Research Institute

Treatments:

Chloroquine
Favipiravir
Hydroxychloroquine
Lopinavir
Ritonavir